US Chondrosarcoma Market

ID: MRFR/Pharma/17472-HCR 100 Pages Satyendra Maurya Last Updated: September 10, 2026
US Chondrosarcoma Market Research Report: Size, Share, Trend Analysis By Types (Conventional chondrosarcoma, Clear cell chondrosarcoma, Myxoid chondrosarcoma, Mesenchymal chondrosarcoma, Dedifferentiated chondrosarcoma, others), By Diagnosis (Biopsy, Imaging, others), By Treatment (Surgery, Therapies, Hemipelvectomy, others) and By End Users (hospitals and clinics, medical research centers, academic institutes, others) - Growth Outlook & Industry Forecast 2025 To 2035
US Chondrosarcoma Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.5%
2024 Market Size$ 168 Million
2025 Market Size$ 178.92 Million
2035 Market Size$ 336 Million
Key Players
Bristol-Myers Squibb
Novartis
Merck & Co.
Amgen
Eli Lilly and Company
Bayer
Trends
  • Emergence of Targeted Therapies
  • Advancements in Diagnostic Technologies
  • Increased Focus on Personalized Medicine
Opportunities
  • Rising Incidence of Chondrosarcoma
  • Advancements in Surgical Techniques
  • Growing Patient Advocacy and Awareness
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Treatment Type (USD Million)
      1. 4.1.1 Surgery
      2. 4.1.2 Radiation Therapy
      3. 4.1.3 Chemotherapy
      4. 4.1.4 Targeted Therapy
    2. 4.2 Construction, BY Diagnosis Method (USD Million)
      1. 4.2.1 Imaging Tests
      2. 4.2.2 Biopsy
      3. 4.2.3 Physical Examination
      4. 4.2.4 Blood Tests
    3. 4.3 Construction, BY Location of Tumor (USD Million)
      1. 4.3.1 Pelvis
      2. 4.3.2 Femur
      3. 4.3.3 Humerus
      4. 4.3.4 Ribs
    4. 4.4 Construction, BY Patient Age Group (USD Million)
      1. 4.4.1 Pediatric
      2. 4.4.2 Adult
      3. 4.4.3 Geriatric
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Merck & Co. (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Amgen (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Eli Lilly and Company (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bayer (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Pfizer (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AstraZeneca (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    4. 6.4 US MARKET ANALYSIS BY LOCATION OF TUMOR
    5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    16. 6.16 CONSTRUCTION, BY LOCATION OF TUMOR, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY LOCATION OF TUMOR, 2024 TO 2035 (USD Million)
    18. 6.18 CONSTRUCTION, BY PATIENT AGE GROUP, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
      3. 7.2.3 BY LOCATION OF TUMOR, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Chondrosarcoma Market Segmentation

US Chondrosarcoma Market By Treatment Type (USD Million, 2025-2035)

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy

US Chondrosarcoma Market By Diagnosis Method (USD Million, 2025-2035)

  • Imaging Tests
  • Biopsy
  • Physical Examination
  • Blood Tests

US Chondrosarcoma Market By Location of Tumor (USD Million, 2025-2035)

  • Pelvis
  • Femur
  • Humerus
  • Ribs

US Chondrosarcoma Market By Patient Age Group (USD Million, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.